文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

意大利注册研究中范可尼贫血患者的长期结局:AIEOP骨髓衰竭研究组的报告

Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology).
PubMed 文献 · Am J Hematol · 2025-06-06

该研究分析了意大利注册研究中193例范可尼贫血患者,其中移植组130例(67.4%),非移植组63例(36.6%)。中位随访7年后,几乎所有患者出现血细胞减少,移植组更常见。自出生起累计总生存率10岁时为91.0%,20岁时为71.6%,30岁时为47.4%,中位生存年龄为29.1岁。40岁时实体/血液系统恶性肿瘤累计发生率为51.7%,移植组恶性肿瘤风险更高(亚分布风险比2.9,95%CI:1.1-7.5,p=0.024)。

要点

  • 范可尼贫血患者自出生起累计总生存率10岁91.0%、20岁71.6%、30岁47.4%,中位生存年龄29.1岁。
  • 40岁时实体/血液系统恶性肿瘤累计发生率为51.7%,移植组风险更高(亚分布风险比2.9,95%CI:1.1-7.5,p=0.024)。
  • 部分未移植患者血细胞减少稳定甚至改善,提示骨髓衰竭并非必然发生,需密切监测造血功能恶化和癌症发生。

核心结论

  • 该研究提供了可能有助于做出可靠临床决策的重要发现。
  • 部分未移植患者血细胞减少稳定甚至改善,证实骨髓衰竭并非所有患者必然发生,强调密切监测造血功能恶化和癌症发生的重要性。

研究设计与样本

  • 分析意大利注册研究中193例范可尼贫血患者,移植组130例(67.4%),非移植组63例(36.6%)。
  • 中位随访7年,关注血液学结局、癌症风险和死亡率。

主要发现

  • 中位随访7年后,几乎所有患者出现血细胞减少,移植组更常见。
  • 自出生起累计总生存率10岁时91.0%,20岁时71.6%,30岁时47.4%;中位生存年龄29.1岁。
  • 按移植指征分层(中度 vs. 重度血细胞减少 vs. 持续不良预后细胞遗传学异常/急性髓系白血病),最后两组5年累计死亡率更高但未达统计学显著(p=0.281)。
  • 癌症是全队列中仅次于感染的第二大死因,头颈部鳞状细胞癌最常见,其次为血液系统肿瘤。
  • 实体/血液系统恶性肿瘤累计发生率在20岁后显著增加,40岁时为51.7%。

临床怎么用

  • 原文未据此给出推荐。
  • 作者指出,部分未移植患者血细胞减少稳定甚至改善,强调密切监测以 surveillance 造血功能恶化和癌症发生的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We analyzed 193 Fanconi anemia patients from the Italian Registry, focusing on hematological outcome, cancer risk, and mortality, both in transplanted (n = 130, 67.4% of the cohort) and non-transplanted (n = 63, 36.6% of the cohort) patients. After a median follow-up of 7 years, almost all patients developed cytopenia that was more frequent in patients receiving hematopoietic stem cell transplantation (HSCT). The cumulative overall survival from birth was 91.0% at age 10 years, 71.6% at age 20, and 47.4% at age 30 years; the median survival age was 29.1 years. When stratifying patients by indication for transplantation (moderate vs. severe cytopenia vs. persistent poor prognosis cytogenetic alterations/acute myeloid leukemia), we found a 5-year cumulative mortality higher, though not significantly (p = 0.281) in the last group. Cancers were the second most common cause of death in the whole cohort after infections. Head and neck squamous cell carcinoma was the most frequent cancer, followed by hematologic neoplasms. The cumulative incidence of solid/hematological malignancy remarkably increased after 20 years of age and was 51.7% at age 40 years. The risk of malignancies was greater in subjects who received HSCT (sub-distribution azard ratio 2.9, 95% CI: 1.1-7.5, p = 0.024). We also identified a small group of patients with stable or even improved cytopenia over time without transplant, thus confirming that bone marrow failure is not automatic in all patients and heightening the importance of tight monitoring to surveil on the worsening of hematopoietic function and cancer occurrence. Overall, this study provides important findings that may help to make robust clinical decisions.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ricci E, Bagnasco F, Pierri F, et al. Long-Term Outcome of Fanconi Anemia Patients From the Italian Registry on Behalf of the Marrow Failure Study Group of the AIEOP (Italian Association for Pediatric Haematology-Oncology). Am J Hematol. 2025. PMID: 40478605. doi:10.1002/ajh.27724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。